Maxwellia has expanded their team of switch experts with two new appointments following their relocation to the Alderley Park Accelerator.
Maxwellia, the UK’s only ‘prescription to over the counter
(OTC)’ medicines company, has expanded their team of switch experts with two new appointments following their relocation to the Alderley Park Accelerator, near Manchester. The hires are part of a rapid growth phase for the company, which aims to build on its product pipeline to become the ‘go to’ for switch innovation.
Alexandra Trehane is Maxwellia’s new Head of Innovation and Dr Emma Quaranta is Senior Regulatory Consultant. Both bring significant OTC experience from their previous roles.
Alexandra joins from GSK where she worked in the Consumer Healthcare business, while Emma brings a breadth of experience in working with regulators at Bell’s Healthcare.
Anna Maxwell, CEO of Maxwellia said, “we’re delighted to welcome Alexandra and Emma during this exciting period of expansion as we relocate to Alderley Park. It is inspiring to be at the heart of a community of innovative and like-minded science professionals as we further develop our portfolio. Growing our team and expert capability will allow us to focus on speedto-market for our new products, enabling more people to access the information and medicines they need without having to bother their GP.”
The NHS is under unprecedented strain with soaring public demand and severe budget constraints. Minor ailments account for one in five GP consultations in England and cost an estimated £2 billion each year. Many of these consultations could simply be avoided if more of the medicines that currently require a prescription were to become available to buy in pharmacies or supermarkets without a prescription.
Alexandra Trehane, Head of Innovation at Maxwellia commented, “successfully navigating the changing pharmacy landscape will be challenging but as a small independent company, Maxwellia is perfectly suited to adapt to the environment quickly. There is huge potential for
growth in the OTC sector and I am thrilled to work for a company destined to play such a key role in helping to reinvigorate the Self Care market and improve public health.”
The value of the UK consumer healthcare market is estimated at £2.6 billion and growing. Switching is a vital means of maintaining the flow of new drugs for Self Care and it is estimated that new switches could add 20% to the UK OTC market by 2030.